LEADER 04484nam 2200997z- 450 001 9910585935803321 005 20231214132936.0 035 $a(CKB)5600000000483127 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/91177 035 $a(EXLCZ)995600000000483127 100 $a20202208d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRisk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (202 p.) 311 $a3-0365-4707-X 311 $a3-0365-4708-8 330 $aThromboembolism is a compelling challenge in cancer care because of its life-threatening nature as well as its impact on specific treatments. Current guidelines do not generally recommend antithrombotic prophylaxis, except in selected categories of patients at high risk of thrombosis. Accordingly, several clinical decision models have been developed to guide the oncologist in thromboembolic risk assessment and targeted prophylaxis. Low-molecular-weight heparins (LMWH) are currently considered as the standard approach in clinical practice guidelines, but recent randomized controlled trials (RCT) indicate that direct oral anticoagulants (DOACs) are effective for the treatment/prophylaxis of cancer-associated thromboembolism. However, many unanswered questions remain on the efficacy and safety of anticoagulants in selected cancer subgroups, and in primary and secondary prevention settings, where anticoagulation needs to be balanced on the risk of bleeding complications. Presently, patient selection remains the main challenge. Improvement in existing VTE risk models or the construction of alternative risk assessment tools are needed in order to ameliorate the risk stratification of cancer patients. This reprint will cover the current clinical evidence supporting the standard of care and emerging treatment/prophylactic options for cancer-associated thromboembolism during both active treatment and simultaneous/palliative care. Tailored approaches based on the use of individualized factors to stratify the thrombotic/bleeding risk in each individual patient are discussed. 606 $aMedicine$2bicssc 606 $aOncology$2bicssc 610 $amultiple myeloma 610 $avenous thromboembolism 610 $arisk assessment models 610 $athromboprophylaxis 610 $adirect oral anticoagulants 610 $acancer-associated venous thromboembolism 610 $athrombosis 610 $apulmonary embolism 610 $aneoplasms 610 $aanticoagulants 610 $acoumarins 610 $alow molecular weight heparins 610 $acancer 610 $aendogenous heparin 610 $aheparanase 610 $aheparan sulfate 610 $ahospice 610 $apalliative care units 610 $alow molecular weight heparin 610 $adeep vein thrombosis 610 $acancer associated thrombosis 610 $aVTE 610 $amalignancy 610 $adirect oral anticoagulant 610 $apancreatic cancer 610 $alow-molecular weight heparin 610 $asurvival 610 $acoagulation activation 610 $alocally advanced breast cancer 610 $aprognostic model 610 $apCR 610 $atreatment 610 $aprophylaxis 610 $aDOAC 610 $asimultaneous care 610 $aintegrated care 610 $alymphoma 610 $aNon-Hodgkin lymphoma 610 $aHodgkin lymphoma 610 $arisk factors 610 $amolecular subtype 610 $aarterial thrombosis 610 $aALK 610 $aROS1 610 $aKRAS 610 $achemotherapy 610 $alow-molecular-weight heparin (LMWH) 610 $aVKA 610 $aUFH 610 $aDOACs 615 7$aMedicine 615 7$aOncology 700 $aFerroni$b Patrizia$4edt$01280411 702 $aRoselli$b Mario$4edt 702 $aGuadagni$b Fiorella$4edt 702 $aFerroni$b Patrizia$4oth 702 $aRoselli$b Mario$4oth 702 $aGuadagni$b Fiorella$4oth 906 $aBOOK 912 $a9910585935803321 996 $aRisk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer$93016900 997 $aUNINA